Morgan Stanley published a research report indicating that based on INNOVENT BIO (01801.HK)'s product revenue performance in the first half and third quarter, the annual growth forecast for the core product Tyvyt has been raised from 15% to 40%. Additionally, the growth forecasts for a series of biosimilar products, including Rituximab, Adalimumab, and Bevacizumab, have also been adjusted upward, with corresponding expectations for R&D and sales costs to increase.

Morgan Stanley currently adjusts the earnings per share forecast for INNOVENT BIO for 2024 to 2026 from a loss of 0.70 yuan, a loss of 0.50 yuan, and a profit of 0.14 yuan to a loss of 0.78 yuan, a loss of 0.47 yuan, and a profit of 0.15 yuan. The Target Price is slightly raised from 66.5 yuan to 67 yuan, with a rating of 'Shareholding.'